As a significant SomaLogic shareholder, Madryn opposes the proposed merger with Standard BioTools because it is fundamentally flawed and one-sided

The proposed merger significantly undervalues SomaLogic, while disproportionately benefiting Standard BioTools and its preferred equity holders at SomaLogic shareholders’ expense.

Our interests are squarely aligned with those of our fellow SomaLogic shareholders. We believe superior alternatives exist for SomaLogic, including as a standalone company, that would maximize value for all stakeholders.

ABOUT MADRYN

REASONS TO VOTE AGAINST

LEARN HOW TO VOTE THE  GREEN PROXY CARD

INVESTOR CONTACT

Saratoga Proxy Consulting
John Ferguson / Joseph Mills
(212) 257-1311
info@saratogaproxy.com

MEDIA CONTACT

Longacre Square Partners
Greg Marose / Joe Germani
(646) 386-0091
madryn@longacresquare.com

STAY UPDATED

Fill out your name and email address to stay updated

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

We Want To Hear From You

Please anonymously submit your comments or concerns using the adjacent form. Note that your personal information will not be saved.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.